LY3499446

LY3499446 is an orally available small molecule inhibitor specifically targeting the KRAS G12C mutation. It covalently binds to cysteine 12 within the switch II pocket of GDP-bound KRAS G12C protein. This binding inhibits mutant KRAS-dependent signaling pathways that drive tumor cell growth and proliferation in cancers harboring this mutation. The drug was developed for potential antineoplastic activity in advanced solid tumors with a focus on non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors with confirmed KRAS G12C mutations. Developed by Eli Lilly and Company, it reached phase I/II clinical trials but development was terminated before completion[1][3][5][9].

Other names

LY3499446LY-3499446LY 3499446